Serum thymidine kinase 1 activity in breast cancer. 2010

Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
Department of Oncology, Hadassah and Hebrew University Medical Centre, Jerusalem, Israel. nisman@hadassah.org.il

OBJECTIVE Thymidine kinase 1 (TK1) is an enzyme involved in DNA synthesis and an important proliferation marker. We explored the association of preoperative serum TK1 activity with clinicopathological parameters and prognosis in terms of recurrence-free survival (RFS) in breast cancer (BC) patients. METHODS TK1 activity in serum of 120 healthy women and 161 BC patients was measured by quantitative ELISA. RESULTS Serum TK1 activity in BC patients was significantly higher than in healthy women (P < 0.0001). In BC patients elevated TK1 activity was significantly associated with advanced T stage (P = 0.015), higher grade (P = 0.013), presence of tumor necrosis (P = 0.006), vascular invasion (P = 0.002), and lack of estrogen receptor (ER) and progesterone receptor (PR) expression (P = 0.0004 and P = 0.003). Higher TK1 activity was found in patients with BRCA1/2 mutations compared to those without the mutation (P = 0.004). Multivariate Cox proportional hazards analyses demonstrated that TK1, adjusted for stage, grade, necrosis, ER and PR negativity was retained as an independent predictor of disease recurrence (Hazard Ratio = 3.9, 95%CI 1.3-11.6, P = 0.013). CONCLUSIONS Elevated serum TK1 is an important risk factor indicating a high proliferation potential of tumors at the time of excision. In multivariate analysis TK1 activity was found to be an independent prognostic factor for RFS.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females

Related Publications

Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
May 2013, Journal of clinical laboratory analysis,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
January 2009, Upsala journal of medical sciences,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
October 1990, British journal of cancer,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
April 2021, ESMO open,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
January 2001, Cancer detection and prevention,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
June 1988, British journal of cancer,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
August 1986, Irish journal of medical science,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
March 2020, Scientific reports,
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
February 2002, Internal medicine (Tokyo, Japan),
Benjamin Nisman, and Tanir Allweis, and Luna Kaduri, and Bella Maly, and Simon Gronowitz, and Tamar Hamburger, and Tamar Peretz
April 2023, Anticancer research,
Copied contents to your clipboard!